The Experts below are selected from a list of 315 Experts worldwide ranked by ideXlab platform
Irene B.l. Boos - One of the best experts on this subject based on the ideXlab platform.
-
Intraarterial Infusion Therapy via a Subcutaneous Port for Limb-Threatening Ischemia: A Pilot Study
CardioVascular and Interventional Radiology, 1998Co-Authors: Ernst-peter K. Strecker, Wladimir Ostheim-dzerowycz, Irene B.l. BoosAbstract:Purpose: To present the initial results of a new percutaneously implantable catheter port system (PIPS) used for long-term intraarterial Infusion Therapy in patients with severe ischemic limb disease. Methods: Ten patients with deep, extended ischemic ulcerations (all 10) and osteomyelitis (6/10) of the foot received intraarterial Infusions of prostaglandine E_1 and antibiotics, if indicated, via a new port catheter system with the port placed subcutaneously above the groin after percutaneous introduction and the catheter tip placed into the superficial or deep femoral artery. Results: Port implantation and repeated port access were uncomplicated. During the follow-up period (mean 11 months, range 1 week–50 months), port migration, leakage, or infection was not observed. Three catheters thrombosed and were opened by fibrinolysis with recombinant tissue plasminogen activator instilled via the port. Treatment success was achieved in 8 patients: relief from rest pain (8 patients), reduction of ulcer size (4/8), and complete healing (4/8). Limb savage rate was 80%. In 2 patients amputation could not be avoided. Conclusion: Selective long-term arterial Infusion Therapy presents a valuable therapeutic regimen for limb salvage. With the new catheter port system, repeated local intraarterial Infusion is safe and simple.
-
intraarterial Infusion Therapy via a subcutaneous port for limb threatening ischemia a pilot study
CardioVascular and Interventional Radiology, 1998Co-Authors: Ernst-peter K. Strecker, Wladimir Ostheimdzerowycz, Irene B.l. BoosAbstract:Purpose: To present the initial results of a new percutaneously implantable catheter port system (PIPS) used for long-term intraarterial Infusion Therapy in patients with severe ischemic limb disease.
-
Intraarterial Infusion Therapy via a Subcutaneous Port for Limb-Threatening Ischemia: A Pilot Study
CardioVascular and Interventional Radiology, 1998Co-Authors: Ernst-peter K. Strecker, Wladimir Ostheim-dzerowycz, Irene B.l. BoosAbstract:Purpose: To present the initial results of a new percutaneously implantable catheter port system (PIPS) used for long-term intraarterial Infusion Therapy in patients with severe ischemic limb disease. Methods: Ten patients with deep, extended ischemic ulcerations (all 10) and osteomyelitis (6/10) of the foot received intraarterial Infusions of prostaglandine E_1 and antibiotics, if indicated, via a new port catheter system with the port placed subcutaneously above the groin after percutaneous introduction and the catheter tip placed into the superficial or deep femoral artery. Results: Port implantation and repeated port access were uncomplicated. During the follow-up period (mean 11 months, range 1 week–50 months), port migration, leakage, or infection was not observed. Three catheters thrombosed and were opened by fibrinolysis with recombinant tissue plasminogen activator instilled via the port. Treatment success was achieved in 8 patients: relief from rest pain (8 patients), reduction of ulcer size (4/8), and complete healing (4/8). Limb savage rate was 80%. In 2 patients amputation could not be avoided. Conclusion: Selective long-term arterial Infusion Therapy presents a valuable therapeutic regimen for limb salvage. With the new catheter port system, repeated local intraarterial Infusion is safe and simple.
Ernst-peter K. Strecker - One of the best experts on this subject based on the ideXlab platform.
-
Intraarterial Infusion Therapy via a Subcutaneous Port for Limb-Threatening Ischemia: A Pilot Study
CardioVascular and Interventional Radiology, 1998Co-Authors: Ernst-peter K. Strecker, Wladimir Ostheim-dzerowycz, Irene B.l. BoosAbstract:Purpose: To present the initial results of a new percutaneously implantable catheter port system (PIPS) used for long-term intraarterial Infusion Therapy in patients with severe ischemic limb disease. Methods: Ten patients with deep, extended ischemic ulcerations (all 10) and osteomyelitis (6/10) of the foot received intraarterial Infusions of prostaglandine E_1 and antibiotics, if indicated, via a new port catheter system with the port placed subcutaneously above the groin after percutaneous introduction and the catheter tip placed into the superficial or deep femoral artery. Results: Port implantation and repeated port access were uncomplicated. During the follow-up period (mean 11 months, range 1 week–50 months), port migration, leakage, or infection was not observed. Three catheters thrombosed and were opened by fibrinolysis with recombinant tissue plasminogen activator instilled via the port. Treatment success was achieved in 8 patients: relief from rest pain (8 patients), reduction of ulcer size (4/8), and complete healing (4/8). Limb savage rate was 80%. In 2 patients amputation could not be avoided. Conclusion: Selective long-term arterial Infusion Therapy presents a valuable therapeutic regimen for limb salvage. With the new catheter port system, repeated local intraarterial Infusion is safe and simple.
-
intraarterial Infusion Therapy via a subcutaneous port for limb threatening ischemia a pilot study
CardioVascular and Interventional Radiology, 1998Co-Authors: Ernst-peter K. Strecker, Wladimir Ostheimdzerowycz, Irene B.l. BoosAbstract:Purpose: To present the initial results of a new percutaneously implantable catheter port system (PIPS) used for long-term intraarterial Infusion Therapy in patients with severe ischemic limb disease.
-
Intraarterial Infusion Therapy via a Subcutaneous Port for Limb-Threatening Ischemia: A Pilot Study
CardioVascular and Interventional Radiology, 1998Co-Authors: Ernst-peter K. Strecker, Wladimir Ostheim-dzerowycz, Irene B.l. BoosAbstract:Purpose: To present the initial results of a new percutaneously implantable catheter port system (PIPS) used for long-term intraarterial Infusion Therapy in patients with severe ischemic limb disease. Methods: Ten patients with deep, extended ischemic ulcerations (all 10) and osteomyelitis (6/10) of the foot received intraarterial Infusions of prostaglandine E_1 and antibiotics, if indicated, via a new port catheter system with the port placed subcutaneously above the groin after percutaneous introduction and the catheter tip placed into the superficial or deep femoral artery. Results: Port implantation and repeated port access were uncomplicated. During the follow-up period (mean 11 months, range 1 week–50 months), port migration, leakage, or infection was not observed. Three catheters thrombosed and were opened by fibrinolysis with recombinant tissue plasminogen activator instilled via the port. Treatment success was achieved in 8 patients: relief from rest pain (8 patients), reduction of ulcer size (4/8), and complete healing (4/8). Limb savage rate was 80%. In 2 patients amputation could not be avoided. Conclusion: Selective long-term arterial Infusion Therapy presents a valuable therapeutic regimen for limb salvage. With the new catheter port system, repeated local intraarterial Infusion is safe and simple.
Zhijun Wang - One of the best experts on this subject based on the ideXlab platform.
-
transradial approach for transcatheter selective superior mesenteric artery urokinase Infusion Therapy in patients with acute extensive portal and superior mesenteric vein thrombosis
CardioVascular and Interventional Radiology, 2010Co-Authors: Mao Qiang Wang, Liping Guo, Han Ying Lin, Feng Yong Liu, Feng Duan, Zhijun WangAbstract:The purpose of this investigation was to assess the feasibility and effectiveness of transradial approach for transcatheter superior mesenteric artery (SMA) urokinase Infusion Therapy in patients with acute extensive portal and superior mesenteric venous thrombosis. During a period of 7 years, 16 patients with acute extensive thrombosis of the portal (PV) and superior mesenteric veins (SMV) were treated by transcatheter selective SMA urokinase Infusion Therapy by way of the radial artery. The mean age of the patients was 39.5 years. Through the radial sheath, a 5F Cobra catheter was inserted into the SMA, and continuous Infusion of urokinase was performed for 5–11 days (7.1 ± 2.5 days). Adequate anticoagulation was given during treatment, throughout hospitalization, and after discharge. Technical success was achieved in all 16 patients. Substantial clinical improvement was seen in these 16 patients after the procedure. Minor complications at the radial puncture site were observed in 5 patients, but trans-SMA Infusion Therapy was not interrupted. Follow-up computed tomography scan before discharge demonstrated nearly complete disappearance of PV–SMV thrombosis in 9 patients and partial recanalization of PV–SMV thrombosis in 7 patients. The 16 patients were discharged 9–19 days (12 ± 6.0 days) after admission. Mean duration of follow-up after hospital discharge was 44 ± 18.5 months, and no recurrent episodes of PV–SMV thrombosis developed during that time period. Transradial approach for transcatheter selective SMA urokinase Infusion Therapy in addition to anticoagulation is a safe and effective Therapy for the management of patients with acute extensive PV–SMV thrombosis.
Paul C Davidson - One of the best experts on this subject based on the ideXlab platform.
-
INTRAVENOUS INSULIN Infusion Therapy: INDICATIONS, METHODS, AND TRANSITION TO SUBCUTANEOUS INSULIN Therapy
Endocrine Practice, 2004Co-Authors: Bruce W Bode, Susan S. Braithwaite, R Dennis Steed, Paul C DavidsonAbstract:Objective: To describe indications for intravenous (IV) insulin Infusion Therapy and glycemic thresholds, discuss methods and protocols, and promote use of and access to IV insulin Infusion Therapy for all appropriate patients in the hospital setting. Results: Randomized, prospectively designed trials support the use of IV insulin Infusion Therapy for patients in the surgical intensive-care unit, including postoperative cardiac patients and patients having myocardial infarction. Among patients in the surgical intensive-care unit, reanalysis of the data suggested no threshold at which benefit occurred above the blood glucose level of 110 mg/dL. In another study, retrospective analysis of data among critically ill medical and surgical patients suggested a target blood glucose level of 145 mg/dL or less. In other populations, the threshold or ideal target blood glucose range has not been determined. Three protocols for IV insulin Infusion are described that maintain blood glucose levels safely below the uppe...
-
Intravenous insulin Infusion Therapy: indications, methods, and transition to subcutaneous insulin Therapy.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2004Co-Authors: Bruce W Bode, Susan S. Braithwaite, R Dennis Steed, Paul C DavidsonAbstract:To describe indications for intravenous (IV) insulin Infusion Therapy and glycemic thresholds, discuss methods and protocols, and promote use of and access to IV insulin Infusion Therapy for all appropriate patients in the hospital setting. Randomized, prospectively designed trials support the use of IV insulin Infusion Therapy for patients in the surgical intensive-care unit, including postoperative cardiac patients and patients having myocardial infarction. Among patients in the surgical intensive-care unit, reanalysis of the data suggested no threshold at which benefit occurred above the blood glucose level of 110 mg/dL. In another study, retrospective analysis of data among critically ill medical and surgical patients suggested a target blood glucose level of 145 mg/dL or less. In other populations, the threshold or ideal target blood glucose range has not been determined. Three protocols for IV insulin Infusion are described that maintain blood glucose levels safely below the upper limit of their respective target ranges without substantial risk of hypoglycemia. The threshold for initiation of IV insulin Infusion is 110 mg/dL for critically ill surgical patients, 140 mg/dL for other medical or surgical patients, 180 mg/dL for patients in whom subcutaneous insulin regimens fail, and 100 mg/dL for pregnant women. The blood glucose target range is 80 to 110 mg/dL for selected critically ill surgical patients, 70 to 100 mg/dL for pregnant women, and 90 to 140 mg/dL for all other patients. Hospitals should develop procedures to make IV insulin Infusion Therapy available to all appropriate patients.
Mao Qiang Wang - One of the best experts on this subject based on the ideXlab platform.
-
transradial approach for transcatheter selective superior mesenteric artery urokinase Infusion Therapy in patients with acute extensive portal and superior mesenteric vein thrombosis
CardioVascular and Interventional Radiology, 2010Co-Authors: Mao Qiang Wang, Liping Guo, Han Ying Lin, Feng Yong Liu, Feng Duan, Zhijun WangAbstract:The purpose of this investigation was to assess the feasibility and effectiveness of transradial approach for transcatheter superior mesenteric artery (SMA) urokinase Infusion Therapy in patients with acute extensive portal and superior mesenteric venous thrombosis. During a period of 7 years, 16 patients with acute extensive thrombosis of the portal (PV) and superior mesenteric veins (SMV) were treated by transcatheter selective SMA urokinase Infusion Therapy by way of the radial artery. The mean age of the patients was 39.5 years. Through the radial sheath, a 5F Cobra catheter was inserted into the SMA, and continuous Infusion of urokinase was performed for 5–11 days (7.1 ± 2.5 days). Adequate anticoagulation was given during treatment, throughout hospitalization, and after discharge. Technical success was achieved in all 16 patients. Substantial clinical improvement was seen in these 16 patients after the procedure. Minor complications at the radial puncture site were observed in 5 patients, but trans-SMA Infusion Therapy was not interrupted. Follow-up computed tomography scan before discharge demonstrated nearly complete disappearance of PV–SMV thrombosis in 9 patients and partial recanalization of PV–SMV thrombosis in 7 patients. The 16 patients were discharged 9–19 days (12 ± 6.0 days) after admission. Mean duration of follow-up after hospital discharge was 44 ± 18.5 months, and no recurrent episodes of PV–SMV thrombosis developed during that time period. Transradial approach for transcatheter selective SMA urokinase Infusion Therapy in addition to anticoagulation is a safe and effective Therapy for the management of patients with acute extensive PV–SMV thrombosis.